Assess whether high doses of ?-3 fatty acids added to standard treatment of patients with acute hearta failure, hypoalbuminemia and high inflammatory activity, promotes an increase in serum albumin

Assess whether high doses of ?-3 fatty acids added to standard treatment of patients with acute hearta failure, hypoalbuminemia and high inflammatory activity, promotes an increase in serum albumin

Assess the effect of high doses of ?-3 fatty acids added to standard treatment of patients with acute hearta failure, hypoalbuminemia and high inflammatory activity on:

• Inflammatory activity (C-reactive protein)
• The development of biomarkers (NTproBNP).
• The prognosis of patients evaluated by the combined event of death from any cause or readmission for heart failure within three months after randomization.

Inclusion Criteria:

• Patients aged 18 years or olders hospitalized for acute heart failure, chronic decompensated or new onset of any etiology, presenting hypoalbuminemia (serum albumin ?3,4 g / dl) and high inflammatory activity (CRP ?2,5 mg / dl).

Exclusion Criteria:

• Impending doom
• Participating in other clinical trials
• Treatment with ?-3 acids in the last month prior to admission
• Percutaneous or surgical treatment of the cause of heart failure during hospitalization.
• Pregnant women.
• Renal failure on dialysis.
• Chronic liver disease Child-Pugh B or C.
• Acute infectious process.
• Active malignant neoplasia.